共 29 条
Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer
被引:114
作者:
Maeda, Shin
Hikiba, Yohko
Shibata, Wataru
Ohmae, Tomoya
Yanai, Ayako
Ogura, Keiji
Yamada, Shingo
Omata, Masao
机构:
[1] Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Chiyoda Ku, Tokyo 1000005, Japan
[2] Univ Tokyo, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan
[3] Shino Test Co, Dept Dev, Sagamihara, Kanagawa 2290011, Japan
关键词:
inflammatory bowel disease;
high-mobility group box 1;
proinflammatory cytokine;
NF-kappa B;
D O I:
10.1016/j.bbrc.2007.06.065
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
High-mobility group box 1 (HMGB1) is a nuclear factor released extracellularly as a proinflammatory cytokine. We measured the HMGB1 concentration in the sera of mice with chemically induced colitis (DSS; dextran sulfate sodium salt) and found a marked increase. Inhibition of HMGB1 by neutralizing anti-HMGB1 antibody resulted in reduced inflammation in DSS-treated colons. In macrophages, HMGB1 induces several proinflammatory cytokines, such as IL-6, which are regulated by NF-kappa B activation. Two putative sources of HMGB1 were explored: in one, bacterial factors induce HMGB1 secretion from macrophages and in the other, necrotic epithelial cells directly release HMGB1. LPS induced a small amount of HMGB1 in macrophages, but macrophages incubated with supernatant prepared from necrotic cells and containing large amounts of HMGB1 activated NF-kappa B and induced IL-6. Using the colitis-associated cancer model, we demonstrated that neutralizing anti-HMGB1 antibody decreases tumor incidence and size. These observations suggest that HMGB1 is a potentially useful target for IBD treatment and the prevention of colitis-associated cancer. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:394 / 400
页数:7
相关论文